Love robotics? Fill out the form below to stay
abreast of the latest news, research, and business
analysis in key areas of the fast-changing
robotics industry
Subscribe to Robotics
Trends Insights


 
Sponsored Links

Advertise with Robotics Trends
[ view all ]
Service and Healthcare
Bookmark and Share
STORY TOOLBOX Print this story  |   Email to a friend  |   RSS feeds
Adept Technologies Supplies Robotics in Tumor Treatment Program
The robotics maker is supplying Lyon Civil Hospitals and Université Lyon with technology to be used in the CLARA program for treating small cancer tumors.
By Robotics Trends Staff - Filed Jan 07, 2011

Adept is providing the robotics component in a method for treating small cancer tumors.

More Service and Healthcare stories
 

Adept Technology Inc., a provider of intelligent vision-guided robotics and global robotics services, is participating in the CLARA (Lyon Auvergne Rhône-Alpes Cancer cluster) program with Lyon Civil Hospitals. Adept is providing the robotics component in a method for treating small cancer tumors.

Currently, early diagnosis of smaller tumors comes via biological testing and medical imaging. The CLARA project introduces a new concept, whereby Adept robots will be employed to automatically locate a treatment probe close to a tumor using a three-dimensional navigation robot guided by a tracking sensor implanted in the body.

In a statement submitted to EH Publishing, Adept Technology Inc. says, “The goal is to demonstrate that an Adept Viper 6-axis robot will ensure perfect positioning of a treatment probe in a tumor for both percutaneous and laparoscopic surgical approaches.”

An experienced surgical and radiological academic team from Université Lyon (UCBL) is overseeing the project. The team’s research is centered on focal therapies, with a critical eye toward engineering and experimental surgery.

“We believe that the instrument designed will have a strong impact on both therapeutic and economic ground,” explains Professor Marc Colombel, head of Surgical Robotics Developments at Lyon Civil Hospitals. Colombel is also a professor at Université Lyon.

For Adept’s part, Rush LaSelle, director of worldwide sales and marketing, says his company is “very excited to be an active participant in developing technology that supports advanced methods for treating cancerous tumors.” He adds, “This opportunity allows Adept to accelerate the development and deployment of safer and more collaborative robotic technologies, further enabling mechatronics to assist the medical community in improving people’s lives.”


Bookmark and Share
STORY TOOLBOX Print this story  |   Email to a friend  |   RSS feeds
  FOLLOW US
Facebook
Now you can follow Robotics Trends and
Robotics Trends Business Review on Facebook